Migraine is a neurological condition that affects an estimated 4.9 million Australians. It is associated with significant wellbeing costs for those living with migraine disease as well as a total estimated economic cost in Australia of $35.7 billion in 2018.
Despite this substantial impact, migraine remains under-diagnosed and under-treated in Australia.
The fourth of this 4-part series revisits the case study of a typical patient presenting with worsening migraines and examines practical aspects of initiating a CGRP-targeted therapy.
Participants must read all 4 issues and then complete the questions on Issue 4 to claim RACGP CPD points.
This program is supported by an independent educational grant provided by Eli Lilly.